MK-2206
- Generic Name
- MK-2206
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H21N5O
- CAS Number
- 1032349-93-1
- Unique Ingredient Identifier
- 51HZG6MP1K
- Associated Conditions
- -
- Associated Therapies
- -
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-11-30
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 63
- Registration Number
- NCT01021748
A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 33
- Registration Number
- NCT00963547
A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 77
- Registration Number
- NCT00848718
Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 104
- Registration Number
- NCT00670488
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath